Semaglutide is a medication that mimics a hormone in the body called GLP-1
Although there has been an increasing literature on the synthesis of biogenic SeNPs and their biomedical uses, there are still some areas of knowledge gaps
Written by Jordan Weiss and reviewed by Daniel Angerbauer, DO, and republished with permission from Atria Health and Research Institute
This approach is non-invasive, easy to incorporate into daily routines, and carries minimal risk
Conducted between June 2011 and March 2013 at 191 sites in 27 countries in Europe, North America, South America, Asia, and Australia this was a randomised, placebo-controlled trial designed to evaluate the efficacy and safety of 3mg liraglutide 'injected subcutaneously once daily, as an adjunct to a reduced-calorie diet and increased physical activity, for weight management in overweight or obese adults who did not have diabetes at baseline.' A total of 3,731 individuals participated in the trial, of whom 2,487 were assigned to lifestyle intervention plus liraglutide and 1,244 to lifestyle intervention with a placebo
